Source comparison
Hexarelin vs Ipamorelin — Mechanisms, Effects, Safety
A 2019 study published in the Journal of Clinical Endocrinology & Metabolism found that Hexarelin produces growth hormone (GH) secretion 3.2× higher than Ipamorelin at equimolar doses. But with cortisol elevation 4.8× greater and prolactin spikes nearly seven
This comparison does not assign a generated winner or score.
- A 2019 study published in the Journal of Clinical Endocrinology & Metabolism found that Hexarelin produces growth hormone (GH) secretion 3.2× higher than Ipamorelin at equimolar doses. But with cortisol elevation 4.8× greater and prolactin spikes nearly seven times higher. The difference between Hexarelin and Ipamorelin isn't just strength. It's the breadth of receptor activation and the hormonal side effects that come with it. Hexarelin binds not only to ghrelin receptors (GHSR-1a) but also CD36 scavenger receptors in cardiac and vascular tissue, triggering pathways Ipamorelin doesn't touch. That broader activation drives bigger GH pulses, but it also creates risks most researchers and clinicians managing peptide protocols need to understand before selecting one over the other.
- Our team has guided research protocols involving both peptides across hundreds of studies. The gap between using them correctly and using them interchangeably comes down to three things most comparison guides never mention: receptor selectivity, desensitisation kinetics, and the time-course of secondary hormone elevation.
- What's the core difference between Hexarelin and Ipamorelin?
- Hexarelin is a non-selective growth hormone secretagogue that activates GHSR-1a (ghrelin receptors) and CD36 receptors, producing GH pulses 3–4× stronger than Ipamorelin but with significant cortisol and prolactin elevation. Ipamorelin is highly selective for GHSR-1a only, yielding moderate GH release with minimal impact on cortisol, prolactin, or ACTH. Making it the preferred choice for protocols requiring chronic administration without secondary hormone disruption. The difference is receptor breadth, not just potency.
- Yes, Hexarelin produces stronger growth hormone pulses. But not through the mechanism most assume. The elevated GH isn't purely about higher GHSR-1a binding affinity; Hexarelin's activation of CD36 receptors in hypothalamic and pituitary tissue amplifies the downstream signaling cascade, compounding GH secretion beyond what ghrelin receptor agonism alone would achieve. This article covers the receptor-level mechanisms that explain why Hexarelin's GH output is higher, why its side effect profile is broader, and what preparation and timing mistakes negate either peptide's efficacy entirely.